Techulon wins $1.9M DARPA contract to develop superbug treatment

05/10/2013 | Genetic Engineering & Biotechnology News

Techulon landed a Phase II, $1.9 million contract with the U.S. Defense Advanced Research Projects Agency to further develop its therapeutic program for multidrug-resistant bacteria, or superbugs. The firm plans to use the money to take a nanotherapeutic agent toward clinical trials.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ